Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic Sells GeneExpress Subscription to Japan s Takeda

NEW YORK, March 27 - Takeda has subscribed to Gene Logic's GeneExpress database and tools, Gene Logic said on Wednesday.

 

The multi-year deal gives the Japanese pharma the use of GeneExpress as well as broad access to Gene Logic's BioExpress and ToxExpress information and tools.

 

Financial terms of the deal, completed in collaboration with Amersham Biosciences KK, Gene Logic's sales and marketing partner in Japan, were not disclosed.


BioExpress includes genomic and clinical data derived from a variety of normal and diseased human tissues, tissues from model animal systems, and human and animal cell lines. ToxExpress is a database containing
expression profiles from organs affected by toxicity and the results of rat and human cell samples treated with various compounds. Gene Logic claims ToxExpress can predict what compounds may cause liver toxicity. GeneExpress was designed to help researchers mine, analyze, index, and visualize data.

 

Takeda, a Japanese drug and vitamin powerhouse, has annual sales topping $7 billion.

 

Earlier in the month, Gene Logic sold a multi-year subscription to its GeneExpress and BioExpress data suites to Japanese pharma Daiichi.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more